Fosun Pharma (600196.SH, 02196) has announced its operating results for the 2025 fiscal year. Driven by breakthroughs in innovative R&D and the upgrade of its global system, the company achieved revenue of RMB 41.662 billion, a year-on-year increase of 1.45%. Within this, revenue from innovative drugs amounted to RMB 9.893 billion, up 29.59% year-on-year, while overseas revenue reached RMB 12.977 billion, an increase of 14.87% year-on-year. The dual growth in these two core indicators reinforces the underlying logic of Fosun Pharma's high-quality development. Net profit attributable to owners of the parent company was RMB 3.371 billion, rising 21.69% year-on-year. Net profit attributable to owners of the parent company after deducting non-recurring items was RMB 2.340 billion, an increase of 1.12% year-on-year. Net cash flow generated from operating activities was RMB 5.213 billion, up 16.45% year-on-year, further strengthening the foundation for high-quality growth.